

1 **Performance of rapid diagnostic tests, microscopy, and qPCR for detection of parasites among**
2 **community members with or without symptoms of malaria in villages with high levels of**
3 **artemisinin partial resistance in North-western Tanzania**

4
5 Rule Budodo¹, Catherine Bakari¹, Salehe S. Mandai¹, Misago D. Seth¹, Filbert Francis², Gervas
6 A. Chacha¹, Angelina J. Kisambale¹, Daniel P. Challe², Daniel A. Petro³, Dativa Pereus^{1,4}, Rashid
7 A. Madebe¹, Ruth B. Mbwambo^{1,4}, Ramadhani Moshi¹, Sijenunu Aaron⁵, Daniel Mbwambo⁵,
8 Abdallah Lusasi⁵, Stella Kajange⁶, Samwel Lazaro⁵, Ntuli Kapologwe⁷, Celine I. Mandara¹, Deus
9 S. Ishengoma^{1, 8*}

10

11 ¹National Institute for Medical Research, Dar es Salaam, Tanzania

12 ²National Institute for Medical Research, Tanga Research Centre, Tanga, Tanzania

13 ³University of Dar es Salaam, Dar es Salaam, Tanzania

14 ⁴Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

15 ⁵National Malaria Control Programme, Dodoma, Tanzania

16 ⁶President's Office, Regional Administration and Local Government, Dodoma, Tanzania

17 ⁷Directorate of Preventive Services, Ministry of Health, Dodoma, Tanzania

18 ⁸Department of Biochemistry, Kampala International University in Tanzania, Dar es Salaam,
19 Tanzania.

20

21 *Correspondence: deusishe@yahoo.com

22 **Abstract**

23 **Background:** Despite the implementation of different control interventions, infections in the
24 communities (among asymptomatic and symptomatic individuals) still play a crucial role in
25 sustaining malaria transmission. This study evaluated the performance of rapid diagnostic tests
26 (RDTs), microscopy, and quantitative PCR (qPCR) in detecting malaria parasites among community
27 members in five villages of Kyerwa district, Kagera region, an area where artemisinin partial
28 resistance (ART-R) has been recently confirmed.

29 **Methods:** A community cross-sectional survey of asymptomatic and symptomatic participants
30 (n=4454) aged ≥ 6 months was conducted in July and August 2023. Malaria infections were
31 detected using RDTs, microscopy, and qPCR (using 18S RNA gene). Performance of RDTs and
32 microscopy was assessed by sensitivity, specificity, and predictive values, using qPCR as the
33 reference method. Factors affecting the accuracy of these methods were explored using a
34 multivariate logistic regression model.

35 **Results:** The prevalence of malaria infections was 44.4% (n = 1979/4454), 32.1% (n = 1431/4454),
36 and 39.8% (n = 1771/4454) by RDTs, microscopy, and qPCR, respectively. The prevalence of *P.*
37 *malariae* and *P. ovale* mono-infection by microscopy was 0.2% (n = 7/4454) and 0.3% (n =
38 12/4454), while by qPCR was 0.4% (n = 16/4454) and 0.5% (n = 24/4454), respectively. The
39 geometric mean parasite densities (GMPDs) by microscopy were 642 (95% confidence intervals (CI)
40 = 570 - 723), 126 (95% CI = 98 - 162), and 124 (95% CI = 82 - 160) asexual parasites/ μL ; while by
41 qPCR, the GMPDs were 1180 (95% CI = 1032 - 1349), 44 (95% CI = 32 - 61), and 50 (95% CI = 29 - 89)
42 parasites/ μL for *P. falciparum*, *P. ovale spp*, and *P. malariae*, respectively. The sensitivity and
43 specificity of RDTs were 94.0% (95% CI = 92.8% - 95.1%) and 87.5% (95% CI = 86.2% - 88.7%),
44 respectively; whereas those of microscopy were 74.6% (95% CI = 72.5% - 76.6%) and 95.2% (95% CI
45 = 94.3% - 96.0%), respectively. The sensitivity of RDTs, and microscopy was low at very low
46 parasitaemia (< 100 parasite/ μL), but increased significantly with increasing parasitaemia, reaching
47 $\geq 99.6\%$ at > 10000 parasites/ μL ($p < 0.001$).

48 **Conclusion:** Higher prevalence of malaria was detected and the performance of RDTs and qPCR
49 were comparable, but microscopy had lower performance. Higher sensitivity by RDTs compared to
50 microscopy, indicate that RDTs are effective for detection of malaria infections for routine case
51 management and surveillance of malaria in this area with confirmed ART-R; and can be utilized in

52 the ongoing plans to develop a response to ART-R.

53 **Key words:** Rapid diagnostic tests, microscopy, qPCR, asymptomatic malaria, artemisinin partial
54 resistance, Northwestern Tanzania

55

56 **Background**

57 Malaria remains a major public health threat, especially among under-fives and pregnant women in
58 Sub-Saharan Africa (SSA) including Tanzania [1]. In 2022, 93.6% of global malaria cases and 95.4%
59 of the deaths due to malaria were reported in the World Health Organization's (WHO) African
60 region (WHO - Afro), where 78.1% of all malaria deaths in this region were among under-fives[2].
61 Tanzania is among the countries with the highest burden, it reported 4.4% of all global malaria
62 deaths in 2022 [2]. Malaria in Tanzania is caused by three species of Plasmodium; *Plasmodium*
63 *falciparum*, *Plasmodium ovale spp*, and *Plasmodium malariae*, with the majority of the infections
64 (>85%) caused by *P. falciparum* [3–6]. Malaria infections due to *Plasmodium vivax* have been
65 sporadically reported, but this parasite species is less prevalent due to the absence of Duffy
66 antigen (among African populations), the binding site for *P. vivax* [7]. Despite the efforts that have
67 been made to control malaria in Tanzania, challenges such as the emergence and spread of
68 insecticide resistance in the vectors [8], antimalarials-resistant *P. falciparum* [9], histidine-rich
69 protein 2/3 (*hrp2/3*) gene deletions [10] and the emergence of invasive *Anopheles stephensi*
70 vectors threaten the progress made in the past two decades[11].

71

72 For effective case management, WHO recommends parasitological confirmation of all suspected
73 malaria cases by rapid diagnostic tests (RDTs) or microscopy before initiating treatment with
74 artemisinin-based combination therapies (ACTs) [12]. Currently, RDTs are the primary diagnostic
75 tool for malaria in Tanzania [13]. Their wide use is due to simplicity, short turn-around time, limited
76 infrastructure requirements, and cost-effectiveness [14]. However, their performance is affected
77 by various factors such as storage conditions, parasitemia, type of antigen, and operator skills [15].
78 Studies show that most RDTs tend to be less sensitive at low parasite densities (such as
79 parasitaemia less than 100 asexual parasites/ μL), thus missing low-density and chronic latent
80 infections, especially in asymptomatic populations, particularly in low-transmission settings
81 [16,17]. Different antigens are used in RDTs including lactate dehydrogenase (LDH), Aldolase,

82 (Aldolase), and *P. falciparum* histidine-rich protein 2 (*pfHRP2*) [18]. Although *pfHRP2*-based RDTs
83 are widely used due to their sensitivity, stability, and abundance, their accuracy may be limited by
84 mutant or *hrp2/3* gene deletions [10], and or prozone effect [19,20]), thus leading to false negative
85 results [21]

86

87 For more than a century, microscopy has remained the gold standard for malaria diagnosis due to
88 its ability for detection and visualization, differentiate parasite species, detection parasite stages
89 (sexual or asexual forms), and quantification of malaria parasites in blood smears [22]. While it
90 offers high specificity and the ability to determine parasite species and quantify parasitemia, its
91 sensitivity can be influenced by factors such as the quality of staining reagents and the skills of
92 microscopists [23]. The limit of detection (LOD) of the expert microscopist can be as low as five (5)
93 parasites/ μ L, while the average LOD for most microscopists ranges from 50 to 100 parasites/ μ L
94 [24]. Other limitations of microscopy include the demand for high-quality microscopy which is well
95 maintained, a laboratory facility, reliable electricity and reagents (fixing and staining reagents, and
96 filtered water at the correct pH) [23,25]. Due to these limitations, most malaria-endemic countries
97 deployed RDTs and have been using them for parasitological confirmation and supporting
98 treatment using ACTs which significantly contributed to reducing the burden of malaria over the
99 past two decades.

100

101 Malaria diagnosis by molecular techniques or nucleic acid detection methods is a highly sensitive
102 and specific method that detects, amplifies, and quantifies DNA specific to malaria parasites [26].
103 Different methods have been developed including quantitative PCR (qPCR) and offer accurate and
104 rapid detection of the parasites, even at low parasite densities (1-5 asexual parasites/ μ L), and can
105 accurately differentiate different *Plasmodium* species, as well as identify mixed or complex
106 infections [16,27,28]. These methods have high sensitivity and specificity which enable them to
107 identify infections in different groups including asymptomatic reservoirs that are missed by
108 conventional diagnostic methods (microscopy and RDTs), and can provide a more accurate
109 assessment of malaria prevalence within a population [4,29]. Additionally, molecular techniques
110 facilitate the detection and monitoring of antimalarial drug resistance by detecting genetic markers
111 associated with resistance. They are also useful in efficacy studies of antimalarial drugs for

112 differentiating recrudescence from new infections and thus establishing the efficacy of antimalarials
113 [30]. However, nucleic acid detection methods have not been widely used in malaria-endemic
114 countries including Tanzania, because they have some major limitations such as infrastructure
115 requirements, lack of skilled experts, and high purchasing and operational costs [31].

116

117 In areas with high transmission, infections in the communities (mainly among asymptomatic
118 individuals) play an important role in malaria transmission [32]. These individuals who remain in
119 the community without health-care harbor parasites infections, more often with low levels of
120 parasitemia that are difficult to detect by conventional diagnostic methods like RDTs and
121 microscopy. This makes detection and targeting of these community infections difficult [21,33]. In
122 addition, there is a paucity of data on how routine diagnostic methods such as RTDs and
123 microscopy perform in the detection of infections among community members during routine
124 surveillance of malaria. The problem is potentially higher in asymptomatic community members,
125 who remain untreated but with high potential of sustaining transmission. In areas with biological
126 threats such as artemisinin partial resistance (ART-R), it is critical to deploy and use highly sensitive
127 tests as part of the response strategy to prevent the spread of resistant parasites. This study aimed
128 to determine the performance of RDTs and microscopy using qPCR as a reference method for the
129 detection of malaria parasites in community members (with or without symptoms) in Kyerwa
130 district of Kagera region, an area where ART-R has been recently confirmed [9]. The findings of this
131 study provide evidence for the potential use of RDTs and microscopy in the surveillance and
132 targeting of community infections (mainly asymptomatic individuals) as part of the response to
133 ART-R in Tanzania.


134

135 **Methods**

136 **Study design and sites**

137 The data and samples used in this study were obtained from a community cross-sectional survey
138 (CSS) that was conducted in five villages in Kyerwa district of Kagera region as described earlier
139 [34]. This was part of the main project on molecular surveillance of malaria in Mainland Tanzania
140 (MSMT) which has been implemented in regions with varying endemicity since 2021 [3,4,34].
141 The five study villages (Kitoma, Kitwechenkura, Nyakabwera, Rubuga and Ruko) are located in

142 Kyerwa district, which is among the eight councils of Kagera region as previously described [34].
143 The villages were selected based on recent research findings which showed that some areas of
144 Kagera region have high levels of parasites with mutations associated with ART-R [9].



145
146 **Figure 1: (A) Map of Tanzania showing the 26 regions including Kagera (gold), (B) study area in**
147 **Kyerwa district (red), and (C) study villages (gold).**

148

149 **Study population, participant enrollment, and data collection**

150 In this study, community members aged 6 months and above were enrolled. The participants
151 reside in the five study villages of Kyerwa district that are part of the longitudinal component of
152 the MSMT project. The participants were asked and provided informed consent to participate in
153 the study. Details of the procedures for enrollment of participants in the CSS were fully described
154 in a recently published paper [34]. Briefly, demographic, anthropometric, clinical, and
155 parasitological data were collected using a questionnaire developed and run-on tablets installed
156 with an Open Data Kit (ODK) software version 4.2 [34]. Participants were appropriately identified
157 using their permanent identification numbers (IDs), interviewed to collect demographic and
158 anthropological data, clinically assessed and examined for any illness, and tested for malaria using
159 RDTs as described earlier [34].

160

161

162 **Sample size and sample collection**

163 The CSS aimed to recruit and obtain blood samples from selected individuals who voluntarily and
164 were conveniently enrolled from a population of 17519 residing in 4144 households, as
165 described earlier [34]. Through a convenient and non-random sampling which was used as
166 described earlier [34], 4454 out of 17519 (25.4%) individuals residing in 768 households were
167 enrolled. Enrolled participants provided finger prick blood for RDTs, thick and thin blood smears
168 for detection of malaria parasites by microscopy, and dried blood spots (DBS) on filter papers
169 (Whatman No. 3, GE Healthcare Life Sciences, PA, USA) for laboratory analyses. All samples were
170 collected from participants using the standard operating procedures (SOPs) of the MSMT
171 project. Briefly, each DBS had three spots, each with about 20 mm diameter equivalent to about
172 50µl of blood [3]. DBS samples were air-dried and packed in zipper bags with silica gel to prevent
173 moisture and fungal infestation. Thick and thin blood smears were prepared in the field, air-
174 dried, and thin films were fixed with absolute methanol. The slides were stained on the same or
175 the following day with 5% Giemsa solution for 45 minutes, and packed in slide storage boxes
176 [35]. All samples were stored at room temperature in the field before delivery to the Genomics
177 Laboratory at the National Institute for Medical Research (NIMR), in Dar es Salaam, for
178 subsequent processing and analyses.

179

180 **Malaria diagnosis using RDT**

181 Detection of malaria infections was done using RDTs under field conditions in which Finger-prick
182 blood was collected from all enrolled participants. Two brands of RDTs were used, Abbott Bioline
183 Malaria Ag Pf/Pan (Abbott Diagnostics Korea Inc., Korea) and Smart Malaria Pf/Pan Ag Rapid Test
184 (Zhejiang Orient Gene Biotech Co. Ltd, China). The RDTs used in the CSS had PfHRP-2 and pLDH
185 antigens. The tests were performed and interpreted following the manufacturers' instructions
186 [36]. RDT results were sent to clinicians to make a final diagnosis in case malaria infections were
187 suspected. Individuals with positive results but without a history of using antimalarial drugs in
188 the last seven days were treated according to the national guidelines for the diagnosis and
189 treatment of malaria [37], while other illnesses were appropriately treated as per national

190 guidelines [38].

191

192 **Detection of malaria parasites by microscopy**

193 The collected blood smears were read at the NIMR Genomics Laboratory after the completion of
194 field activities. Two experts, WHO-certified microscopists read the blood smears for detection of
195 malaria parasites, identification and quantitation of asexual and sexual (gametocytes) stages,
196 and detection of different *Plasmodium* species as described earlier [23]. In case of discrepancy, a
197 third reading was performed by an independent microscopist blinded to the results of the first
198 two readers. In all positive smears, asexual and sexual parasites were counted against 200 and
199 500 white blood cells (WBCs), respectively. Parasite density was obtained by multiplying the
200 parasite counts by 40 for asexual and 16 for sexual parasites, assuming each microliter of blood
201 contained 8000 WBCs [39]. A blood slide was considered negative for *Plasmodium* species if no
202 parasites were detected in at least 200 oil-immersion, high-power fields on the thick film. Quality
203 control of smears was done as previously described [23].

204

205 **DNA extraction and detection of malaria parasites using real-time qPCR**

206 DNA was extracted from three punches of DBS, and each punch had 6mm, representing
207 approximately 25µl of blood. The extraction was done using 0.5% Chelex-Tween 20 (Bio-Rad
208 Laboratories, Hercules, CA, USA), and the final DNA was eluted in a volume of approximately
209 100µl of nuclease-free water as previously described [3]. Species-specific qPCRs targeting 18S
210 ribosomal Ribonucleic acid (rRNA) subunit were performed as described earlier [3], and the
211 reactions were run on the Bio-Rad CFX 96 Opus real-time PCR detection system (Bio-Rad,
212 California, USA), with CFX Maestro software version 2.2. A separate qPCR assay was run for each
213 species: *P. falciparum*, *P. malariae*, and *P. ovale spp.* (simultaneously detecting both *P. ovale*
214 *curtis* and *P. ovale wallikeri*) in a final volume of 12.5uL reaction mixture containing 10uL of
215 master mix and 2.5uL of DNA template. qPCR was run for 40 cycles for all species except *P.*
216 *malariae* which was run for 45 cycles, and quantification of the parasites was done by running
217 standard curves using 10-fold serial dilution of engineered plasmids as earlier described [3].
218 Analysis of *P. vivax* was not done because it was rarely detected in our recent studies [3,4], but
219 this will be done in the future using a pooling strategy that is being optimized.

220

221 **Data management and analysis**

222 All clinical and parasitological data were collected using electronic data capture tools installed on
223 tablets using ODK software version 4.2. The data were transmitted to the central server at NIMR
224 in Dar es Salaam in real-time or once the internet connection was working, and they were
225 validated daily concurrently with field activities. After completion of field activities, the data
226 were downloaded into Microsoft Excel for further cleaning. Data analysis was done using STATA
227 software version 13 (StataCorp, Texas, USA) and R software v4.4.1. Descriptive statistics
228 including frequencies, percentages, medians, and interquartile ranges (IQRs) were used to
229 summarize the data. Sensitivity, specificity, positive and negative predictive values, and accuracy
230 of RDTs and microscopy were determined using 2×2 contingency tables, with qPCR as the gold
231 standard [40]. For the three diagnostic techniques (RDTs, microscopy, and qPCR), Pearson Chi-
232 squared test was used to assess the differences in malaria prevalence across the three age
233 groups (under-fives, school children aged 5 - <15 years, and adult individuals with ≥15 years
234 old), sex, history of fever in the past 48 hours, fever at presentation (axillary temperature
235 ≥37.5°C), and area of residence [16,23]. The accuracy of RDTs and microscopy when compared
236 to qPCR (defined as correct results with negative or positive tests divided by all results) were also
237 determined as previously described [41]. Predictors of risk of obtaining false negative RDTs and
238 microscopy results as determinants of sensitivities of RDTs and microscopy were computed using
239 a multivariate logistic regression model, with adjustments for sex, age groups, history of fever in
240 the past 48 hours, fever at presentation, parasite densities (<100, 100-1000, 1001-5000, 5001-
241 10000, and >10000 asexual parasites/μL), and area of residence. For predictors of risk of
242 obtaining false positive RDTs and microscopy results as determinants of the specificity of RDTs
243 and microscopy, adjustments were done for sex, age groups, history of fever in the past 48
244 hours, fever at presentation, and area of residence. All results with a p-value <0.05 were
245 considered significant. Concordance between the three methods was calculated using Cohen's
246 Kappa coefficient (κ), and $\kappa < 0.20$ indicated poor agreement, 0.21–0.40 was considered to be
247 fair, 0.41–0.60 was moderate, 0.61–0.80 was good agreement, 0.81–0.99 was very good and
248 1.00 indicated perfect agreement [16].

249

250 **RESULTS**

251 **Baseline characteristics of the population**

252 The CSS which collected the data and samples used in this study was undertaken from 14th July to
253 02nd August 2023, and enrolled 4454 individuals from the five villages of Kyerwa district in Kagera
254 region. The data and samples from all participants were available and were used in this study.
255 The median age of study participants was 14 (IQR = 6.7 – 36.0) years; 59.3% (n = 2643/4454) were
256 females, and the rest were males (40.7%, n = 1811/4454). Of all individuals, 48.2% (n =
257 2146/4454) were aged ≥ 15 years, while under-fives accounted for 18.7% (n = 835/4454) and
258 33.1% (n = 1473/4454) were school children (aged 5 - <15 years). Among the five villages,
259 Nyakabwera had 27.9% (n = 1243/4454) of the study participants and Rubuga had 21.9% (n =
260 974/4454). Each of the three remaining villages had less than 20.0%, but had above 15.0% of the
261 participants (Kitwechenkura with 17.3%, n = 769/4454; Ruko had 17.0%, n = 759/4454; and
262 Kitoma had 15.9%, n = 709/4454). Overall, 30.1% (n = 1341/4454) of the participants had a
263 history of fever in the past 48 hours before the survey, while only 3.1% (n = 136/4454) had fever at
264 presentation (with axillary temperature $\geq 37.5^\circ\text{C}$). Among all participants, 6.5% (n = 289/4454) had
265 a history of medication use in the past seven days, and 89.3% (n = 258/289) of these reported that
266 they used Artemether-Lumefantrine (AL) for the treatment of uncomplicated malaria (**Table 1**).
267 Other antimalarial drugs reported to have been used included injectable artesunate (by 1.0%, n =
268 3/289), Metakelfin (by 0.7%, n = 2/289), Quinine (0.3%, n = 1/289), and other unspecified
269 antimalarial drugs (0.3%, n = 1/289).

270


271 **Prevalence of malaria by RDTs, microscopy, and qPCR**

272 All enrolled participants were tested with the three methods, and 44.4% (n=1979/4454) had
273 positive results by RDTs, while the prevalence was 32.1% (n = 1431/4454) by microscopy and
274 39.8% (n=1771/4454) by qPCR. The differences in the prevalence by the three methods were
275 statistically significant ($p < 0.001$). The highest prevalence of malaria infections by RDT (68.5%,
276 n=520/759) and microscopy (51.6%, n=392/759) was in Ruko, while by qPCR, the highest
277 prevalence was in Rubuga (55.9%, n=544/974); with significantly high variations among the
278 villages ($p < 0.001$). Nyakabwera had the lowest prevalence by all methods; RDTs (14.5%, n=
279 180/1243), microscopy (9.3%, n=116/1243) and qPCR (13.9%, n=173/1243); and the differences

280 were statistically significant ($p < 0.001$ for all tests) (Table 2).

281


282 Using all three test methods, males and school children had significantly higher prevalence
283 ($p < 0.05$ for all comparisons, except with RDT for under-fives vs. school children) (Table 2; Fig. 2A
284 and Fig. 2B). Among individuals with a history of fever within the past 48 hours, the majority
285 tested positive by all methods (88.4%, $n = 1186/1341$ by RDTs; 63.2%, $n = 847/1341$ by
286 microscopy; and 76.1%, $n = 1021/1341$ by qPCR). The prevalence was also higher for those with
287 fever at presentation (axillary temperature $\geq 37.5^\circ\text{C}$), with 79.4% ($n = 108/136$) by RDTs, 68.4%
288 ($n = 93/136$) by microscopy, and 74.3% ($n = 101/136$) by qPCR. Of the participants who reported
289 that they used AL within the past seven days, 96.5% ($n = 249/258$) had positive results by RDTs;
290 37.6% ($n = 97/258$) were positive by microscopy while 64.0% ($n = 165/258$) had positive results
291 by qPCR (Table 2).



292

293 **Figure 2A. Prevalence of malaria infections by RDTs, microscopy, and qPCR among individuals of**
294 **different age groups**

295 ***** $p = 0.001$, ** $p < 0.01$, ns = Not significant**



296
297

298 **Figure 2B. Prevalence of malaria infections by RDTs, microscopy, and qPCR among male and**
299 **female participants.**

300 ***** p=0.001, **p<0.01, *p<0.05**

301
302 **Prevalence of *Plasmodium falciparum*, non-falciparum species and parasitaemia**

303 Based on microscopy, the prevalence of *P. falciparum*, *P. malariae*, and *P. ovale* mono-infections
304 was 28.7% (n = 1279/4454), 0.2% (n = 7/4454), and 0.3% (n = 12/4454), respectively. Mixed
305 infections occurred in 3.0% (n = 133/4454) of the samples, and these included double infections,
306 with 2.1% (n = 93/4454) of *P. falciparum*/*P. malariae* and 0.9% (n = 39/4454) with *P. falciparum*/*P.*
307 *ovale*, and triple infections of *P. falciparum*/*P. malariae*/*P. ovale* which occurred in one sample
308 (0.02%; n = 1/4454). By qPCR, the prevalence of *P. falciparum*, *P. malariae*, and *P. ovale* mono-
309 infections was 35.3% (n = 1572/4454), 0.4% (n = 16/4454), and 0.5% (n = 24/4454), respectively.
310 The proportion of samples with positive results due to mixed infections of different *Plasmodium*

311 species by qPCR was 3.6% (n = 159/4454). These mixed infections included double infections of *P.*
312 *falciparum*/*P. malariae* at 0.9% (n = 40/4454), *P. falciparum*/*P. ovale* at 2.6% (n = 114/4454), and
313 0.04% (n = 2/4454) had *P. ovale*/*P. malariae*, while triple infections of *P. falciparum*/*P.*
314 *malariae*/*P. ovale* occurred in 0.07% (n = 3/4454) of the samples (Table 3).

315


316 The geometric mean parasite densities (GMPDs) by microscopy were 642 parasites/ μ L (95% CI =
317 570 - 723) for *P. falciparum*, 124 parasites/ μ L (95% CI = 97 - 160) for *P. malariae*, and 126
318 parasites/ μ L (95% CI = 82-194) for *P.ovale* spp (Fig. 3A). The parasite densities of *P. falciparum*
319 were significantly lower (p<0.001) among adults aged \geq 15 years (with the mean parasite density
320 of 246 parasites/ μ L, 95% CI = 206-293), while the highest densities were among under-fives (with
321 1915 parasites/ μ L; 95% CI = 1398 - 2623), 209 parasites/ μ L (70 - 629), and 288 parasites/ μ L (165 -
322 504) for *P. falciparum*, *P. ovale*, and *P. malariae*, respectively. The GMPDs of *P. falciparum* were
323 higher in males compared to females (with 759 parasites/ μ L, 95% CI = 635 - 908 for males versus
324 563 parasites/ μ L, 95% CI=481-660 for females, p=0.014) and in Ruko (847 parasites/ μ L, 95% CI =
325 679 - 1057, p=0.034) compared to other villages (Table 4). By qPCR, the GMPDs of *P. falciparum*,
326 *P. ovale*, and *P. malariae* were 1180 parasites/ μ L (95% CI = 1032 - 1349), 44 parasites/ μ L (95% CI =
327 32 - 61), and 50 parasites/ μ L (95%CI = 29 - 89) (Fig 3B). The parasite densities of *P. falciparum*
328 were lower among adults aged \geq 15 years, with a mean parasite density of 566 parasites/ μ L, 95%
329 CI = 460-697, p<0.001), compared to under-fives who had higher densities (with a mean parasite
330 density of 2076 parasites/ μ L, 95% CI = 1462 - 2948, p<0.001). The mean parasite densities for *P.*
331 *ovale* were also significantly higher among under-fives (with 118 parasites/ μ L, 95% CI = 59-236,
332 p=0.002), while the GMPD of *P. malariae* in under-fives (67 parasites/ μ L, 95% CI=15-300, p=0.272)
333 was also higher, but the differences among age groups were not statistically significant.
334 Parasitemia due to *P. falciparum* was higher in males (with 1401 parasites/ μ L, 95% CI = 1143-
335 1717, p=0.015) while with *P. malarie* and *P. ovale*, the differences in GMPD among females and
336 males were not statistically significant (p=0.528, and p=0.225 for *P. malarie*, and *P. ovale*,
337 respectively) (Table 4).

338

339

340

341
342
343
344



345
346
347
348
349
350
351
352
353
354

Figure 3: Violin plots representing the distribution of parasite densities detected for *P. falciparum*, *P. malariae*, and *P. ovale*. Panel A shows densities detected using microscopy, while Panel B presents those detected using PCR. The plots highlight the variability in parasite densities for each species, with the shape and width of the violins indicating the spread and frequency of the data points.


Performance of RDTs, microscopy, and qPCR for malaria detection

Of all participants (n = 4454), 1651 (37.1%, 95% CI = 35.3-38.9) were positive by both RDTs and qPCR, while 1328 participants (29.8%, 95% CI = 28.2-31.5) tested positive by both microscopy and

355 qPCR (Table 5 and Fig. 4). With qPCR as the reference method, the sensitivity of RDTs and
356 microscopy was 93.2% (95% CI = 92.0 - 94.4) and 75.0% (95% CI = 72.9 - 77.0), respectively. The
357 specificity of RDTs was 87.8% (95% CI = 86.5 - 89.0), while that of microscopy was 96.2% (95% CI =
358 95.4 - 96.9) (Table 5 and Fig 4). The diagnostic accuracy of RDTs was 89.9% (95% CI = 89.0-90.8),
359 and the accuracy was 87.7% (86.7-88.7) for microscopy. Microscopy showed a higher positive
360 predictive value of 92.8% (95% CI = 91.4 - 94.0) compared to RDTs which had a positive predictive
361 value of 83.4% (95% CI = 82.0 - 84.8). Conversely, the negative predictive value was higher for RDT
362 than for microscopy, 95.2% (95% CI = 94.3 - 95.9) and 85.30% (95% CI = 84.3 - 86.3), respectively.
363 Both RDTs and microscopy had better agreement with qPCR, with Cohen's kappa values of 0.79
364 (95% CI = 0.78-0.81) and 0.74 (95% CI = 0.71-0.76), respectively (Table 5).

365
366 The sensitivities of RDTs and microscopy varied at different levels of parasitemia, with the lowest
367 sensitivity of microscopy of 40.4% at <100 parasites/ μ L while for RDTs, the sensitivity at
368 parasitaemia <100 parasites/ μ L was 76.6% (Fig 5). The sensitivity of both RDTs and microscopy
369 increased with an increase in parasitemia, from 70.7% and 94.0% at 100-1000 parasites/ μ L to
370 92.3% and 100% at >5000-10000 parasites/ μ L by microscopy and RDTs, respectively. The
371 sensitivity was over 99.6% at very high parasite densities (>10000 parasites/ μ L) (Fig 5). The
372 sensitivity of both methods (RDTs and microscopy) was significantly higher at high parasitaemia
373 (aOR >100, p<0.001) and among individuals with a history of fever (aOR > 1.30, p<0.001) (Table
374 6A). The specificity of RDTs was significantly affected by age (aOR >0.40, p<0.001), history of fever
375 (aOR =0.08, p<0.001), and fever at presentation (aOR = 0.59, p<0.05) while the specificity of
376 microscopy was not affected by any of the demographic and clinical variables (p>0.05) (Table 6B).


377



378

379 **Figure 4. Flow chart showing tests performed and their diagnostic performances**

380 TP: True Positive; FP: False Positive; TN: True Negative; FN: False Negative



381

382 **Figure 5. Sensitivity of RDTs and microscopy at different levels of parasitemia. Bars represent**
383 **proportion of cases with positive results by different categories of parasite density, asexual**
384 **parasites/ μ L (black bars =microscopy, n = 4454; and clear bars =RDTs, n = 4454); Solid line =**
385 **sensitivity of RDTs and dotted line = sensitivity of microscopy.**

386

387 **DISCUSSION**

388 This community cross-section survey was conducted to assess the performance of three malaria
389 diagnostic methods (RDTs, microscopy and qPCR) among community members (with or without
390 symptoms of malaria) with a focus on asymptomatic individuals in areas where increasing levels
391 of parasites with ART-R have been recently reported [42]. The study area is located near Rwanda
392 and Uganda borders with human movements and where ART-R has been confirmed [9] Thus, this
393 area is of high interest and it is being targeted as part of the response to ART-R with a broader
394 focus on the Great Lakes Region of Africa. In this and other communities, recent studies have

395 reported high prevalence of malaria among asymptomatic individuals and identified vulnerable
396 groups (eg. males, school children, individuals with low socio-economic status and those living in
397 poorly constructed houses) which need to be targeted by malaria interventions including
398 intensified surveillance based on use of sensitive diagnostic methods [34,43]. In this study, the
399 overall prevalence of malaria was higher by RDT compared to microscopy, and it was also higher
400 among males, school children and individuals with fever history or fever at presentation. The
401 prevalence of malaria infections was higher by RDTs followed by qPCR while microscopy had the
402 lowest prevalence. The GMPDs of all species (*P. falciparum*, *P. malariae* and *P. ovale*) were higher
403 by qPCR compared to microscopy. Using qPCR as the gold standard, RDTs had a higher sensitivity
404 compared to microscopy while the specificity was higher for microscopy compared to RDTs, and
405 the sensitivity of both RDTs and microscopy increased with increasing parasite density. These
406 findings support the use of RDTs as a reliable parasite detection method for targeting community
407 members, particularly asymptomatic individuals, and can potentially be utilized in the ongoing
408 plans to develop a response to ART-R [9,42].

409
410 The prevalence of malaria infections was higher for RDTs while microscopy had the lowest
411 prevalence. RDTs had the highest prevalence even for individuals of different age groups and sex.
412 The high prevalence by RDTs could be due to the persistence of HRP2 antigens, which can remain
413 detectable for up to four weeks after effective treatment, even after complete clearance of
414 malaria parasites [42]. Higher prevalence of RDTs could also be caused by human errors during
415 interpretation of results as some bands on test lines can be reported as present while the test is
416 actually negative [44]. This means that some of the RDT positive results could actually be false
417 positives, resulting high false positive results which has been associated with unwarranted
418 prescription of antimalarials. History of antimalarial use within one to two weeks prior to testing
419 may provisionally may help to identify individuals with false positive results as shown in this study
420 that such individuals were more likely to be positive by RDTs and qPCR compared to microscopy,
421 but cannot rule out failed clearance (recrudescence) or new infection.

422
423 The lower prevalence by microscopy compared to RDTs could be due to its low sensitivity
424 particularly in low parasite density among asymptomatic individuals, quality of blood smears, and

425 technical limitations. Previous studies have shown that low parasitemia below the limit of
426 detection of microscopy is associated with an increasing rate of false negative results since a
427 number of positive samples with low density infections are missed [45,46]. Quality and technical
428 limitations including the optical condition of microscopes, skills of slide readers, smearing and
429 slide staining quality have also been reported to affect microscopy results [47–49]. With poorly
430 prepared smears or faulty microscopes, even appropriately-trained readers can potentially miss
431 or misdiagnose malaria. Poorly trained microscopists can also contribute to this problem even if
432 smears have been well prepared [47]. However, the study team used high quality reagents and
433 experienced experts suggesting that these factors could not have potentially affected the results
434 of this study . Thus, more studies will be needed to further tease out the poor performance of
435 microscopy in similar study groups and areas of comparable transmission intensities.

436
437 Parasite densities were significantly higher for qPCR compared to microscopy, and this could be
438 attributed to the low detection limit of qPCR compared to microscopy. Studies have shown that
439 qPCR can identify as few as one parasite per microliter of blood, whereas microscopy typically
440 requires a minimum threshold of around 50-100 parasites/ μ L) to ensure accurate identification
441 [16,17]. Furthermore, parasitemia due to *P. falciparum* was higher compared to *P. ovale* spp and
442 *P. malariae* with the highest *P. falciparum* parasitemia in under-fives. This could be due to
443 differences in the biology of these malaria parasite species whereby *P. falciparum* is known to be
444 highly pathogenic compared to other species, and this it is capable of rapid replication and the
445 potential to evade the immune system leading to high parasitaemia [4,50]. The findings of this
446 study are similar to what was reported in previous studies [51]. Low level of immunity among
447 under-fives could be the main reason for higher parasitemia in this group, and this should always
448 be considered when implementing case management strategies in under-fives [52].

449
450 While both RDTs and microscopy worked well, RDTs had a higher diagnostic accuracy than
451 microscopy, and higher sensitivity but substantially lower specificity and PPV compared to
452 microscopy. The specificity and PPV of RDTs were lower as expected, and it was most likely due to
453 HRP2/3 protein residues that tend to persist even after the infection has been cleared with
454 antimalarials [31,36]. RDTs were more sensitive than microscopy even at low parasitemia (<100

455 asexual parasites/ μ L), with the sensitivity of the two methods increasing as parasite density
456 increased. The lower sensitivity of microscopy was potentially attributed to lower parasite
457 density, as this study focused on community members whereby majority of the study participants
458 (69.9%) were asymptomatic, with some of them carrying low-density infections below the
459 detection limit of microscopy. The false positivity rate was higher with RDTs (12.2%) compared to
460 microscopy (3.8%) suggesting that using RDTs particularly in community members made of mainly
461 asymptomatic individuals should be properly assessed to avoid unwanted prescription of
462 antimalarials, while the false negativity rate was higher with microscopy (25.0%) and lower with
463 RDTs (6.8%). This agrees with the historical use of microscopy as a confirmatory test for malaria
464 diagnosis due to its higher specificity [53]. However, as demonstrated from this study, RDTs,
465 which are the current option for malaria testing at health facilities, had high sensitivity but low
466 specificity, and microscopy which is the current gold standard, has high specificity but relatively
467 lower sensitivity. Molecular detection by qPCR is highly sensitive and specific, but not feasible in
468 clinical settings. More efforts need to be invested to determine the most ideal approach for
469 malaria diagnosis in areas with heterogeneous malaria transmission. Such test will also be critical
470 for supporting malaria surveillance within the ongoing elimination efforts and in responding to
471 ART-R.

472 Parasite density, age, and sex were found to affect the sensitivity and specificity of RDTs and
473 microscopy in various ways in this study. The sensitivity of both RDTs and microscopy increased
474 with increasing parasite density and more false negatives were associated with low parasite
475 density. Similar to what has been reported by others [45,54], the sensitivity of microscopy and RDT
476 becomes very low below 100 parasites / μ L or < 0.002% parasitaemia for RDTs and <50 parasites
477 / μ L or < 0.001% parasitaemia for microscopy. This implies that at low parasite densities, a
478 considerable proportion of positive individuals may be missed by the tests, and this is of concern
479 especially in areas targeting elimination as these are characterized with low level infections. The
480 sensitivity of RDTs decreased with increasing age and this was similar to what was reported by
481 others [55–57]. This could be explained by age-dependent immunity which develops following
482 repeated exposure to infections, that may suppress parasites and result in low densities below
483 detection threshold [56,58]. The specificity of RDTs increased with age, which is in agreement to
484 what was previously reported by others [59–61], although other studies reported no age-specific

485 trends[16,62]. The effect of age on specificity is thought to be influenced by the parasite density,
486 which is related to the improvement of the immune system with age [59].

487 This study had two limitations. Firstly, a history of fever within the past two days and a history of
488 antimalarial use within the previous seven days were based on self-reported information,
489 increasing their potential recall bias. Participants or guardians of participants were the only source
490 of information and the team had no means to ascertain their responses. However, the findings
491 reported in this study are similar to what have been previously reported [23], suggesting that the
492 responses reported in this study could potentially represent the actual status of fevers in the
493 communities. Secondly, the study covered only one district of Kagera region where ART-R has
494 recently been confirmed and the Ministry of Health is planning to implement a response strategy
495 for ART-R. Thus, the findings from this study cannot be used to represent general performance of
496 these three diagnostic methods in other areas of Mainland Tanzania. Despite these limitations, the
497 finding of this study demonstrates higher performance of RDTs compared microscopy with qPCR as
498 the reference method, suggesting that RDTs can be used as reliable methods for detection of
499 malaria in communities with focus on areas with reported ART-R or ongoing malaria elimination
500 strategies.

501

502 **CONCLUSION**

503 This study revealed that RDTs were more sensitive and accurate but less specific compared to
504 microscopy in detecting malaria parasites among community members, with a high proportion of
505 asymptomatic individuals. The false positivity rate was higher with RDTs while the rate of false
506 negative results was high with microscopy. The performances of both RDTs and microscopy were
507 poor at very low parasite density (<100 parasite/ μL), but increased with an increase in parasite
508 density. The higher sensitivity and diagnostic accuracy of RDTs compared to microscopy supports
509 the routine use of RDTs for case management and surveillance of asymptomatic malaria in this
510 area with confirmed ART-R. Due to lower performance of microscopy particular among individual
511 with low parasite density, RDTs usage in routine malaria diagnostic services should be prioritized,
512 however, microscopy should be utilized for malaria confirmation purposes due to its high
513 specificity. To ensure the high quality of malaria diagnosis results, the performance of RDTs and
514 microscopy should be regularly monitored for supporting appropriate treatment of malaria

515 infections with effective antimalarials as part of the strategies to fight ART-R

516

517

518 **Ethics approval and consent to participate**

519 This CSS was part of the MSMT project whose protocol was reviewed and approved by the
520 Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research
521 (NIMR). Authorization to conduct the study was obtained from the President’s Office, Regional
522 Administration and Local Government (PO-RALG), regional authorities, and the District Executive
523 Directors. Information about the CSS was disseminated in the community through their village
524 mobilization teams for two consecutive days preceding the survey. Before participating in the
525 survey, verbal and written informed consent were sought and obtained from all participants or
526 parents/guardians in the case of children.

527

528 **Availability of data and materials**

529 The data used in this paper are available and can be obtained upon request from the
530 corresponding author.

531

532 **Competing interests**

533 The authors declare that they have no competing interests.

534

535 **Funding**

536 This work was supported in full by the Bill & Melinda Gates Foundation [grant number 002202].
537 Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic
538 License has already been assigned to the Author Accepted Manuscript version that might arise
539 from this submission.

540

541 **Authors contribution**

542 DSI developed the idea, supervised study implementation, data analysis, and interpretation of the
543 results. FF, DPC, and MDS were involved in data collection, analysis, and results interpretation.
544 RBM drafted the manuscript and all authors revised the manuscript. DSI revised and finalized the

545 manuscript and all authors read and approved the manuscript.

546

547 **Acknowledgments**

548 The authors sincerely thank the participants for their willingness to participate in the CSS,
549 consenting, and contributing to the study. They also extend their gratitude to the data collection
550 and laboratory teams for their valuable contributions, including Ezekiel Malecela, Oswald Oscar,
551 Ildephonse Mathias, Gerion Gaudin, Kusa Mchaina, Hussein Semboja, Sharifa Hassan, Salome
552 Simba, Hatibu Athumani, Ambele Lyatinga, Honest Munishi, Anael Derrick Kimaro, Ally Idrissa and
553 Amina Ibrahim. Special thanks to the finance, administrative, and logistic support teams at NIMR:
554 Christopher Masaka, Millen Meena, Beatrice Mwampeta, Neema Manumbu, Arison Ekoni, Sadiki
555 Yusuph, John Fundi, Fred Mashanda, Amir Tununu and Andrew Kimboi. The support from the
556 management of NIMR, NMCP and PO-RALG was critical to the success of this CSS, and it is
557 therefore appreciated. The team extends gratitude for the technical and logistics support from
558 partners at Brown University, the University of North Carolina at Chapel Hill, the CDC Foundation
559 and the Bill and Melinda Gates Foundation team.

560

561 **Abbreviations and acronyms**

562 ACT Artemisinin-based combination therapy
563 AL Artemether-Lumefantrine
564 aOR Adjusted odds ratio
565 ART-R Artemisinin partial resistance
566 CI Confidence interval
567 CDC Centers for Disease Control and Prevention
568 cOR Crude odds ratios
569 CSS Cross-sectional survey
570 DBS Dried blood spots
571 DMFP District malaria focal person
572 GMPD Geometric Mean Parasite Density
573 IDs Identification numbers
574 IPTp Intermittent preventive treatment

575 IQR Interquartile range
576 IRS Indoor residual spraying
577 ITN Insecticides treated nets
578 LSM Larval source management
579 MRCC Medical Research Coordinating Committee
580 MSMT Molecular surveillance of malaria in Tanzania.
581 NIMR National Institute for Medical Research
582 NMCP National Malaria Control Program
583 ODK Open Data Kit software
584 ORs Odds ratio
585 PCA Principal component analysis
586 PO-RALG President's Office, Regional Administration and Local Government
587 RDTs Rapid diagnostic tests
588 rRNA Ribosomal Ribonucleic Acid
589 SMPS School-children Malaria Parasitological Survey
590 SOPs Standard Operating Procedures
591 WHO World Health Organization

592

593 REFERENCES

- 594 1. Okoyo C, Githinji E, Muia RW, Masaku J, Mwai J, Nyandieka L, et al. Assessment of malaria
595 infection among pregnant women and children below five years of age attending rural health
596 facilities of Kenya: A cross-sectional survey in two counties of Kenya. PLoS One. 2021;16:e0257276.
597 2. WHO. World Malaria Report 2023. Geneva: World Health Organization; 2023.
598 3. Popkin Hall ZR, Seth MD, Madebe RA, Budodo R, Bakari C, Francis F, et al. Malaria species
599 positivity rates among symptomatic individuals across regions of differing transmission intensities
600 in Mainland Tanzania. J Infect Dis 2023. <http://dx.doi.org/10.1093/infdis/jiad522>
601 4. Popkin-Hall ZR, Seth MD, Madebe RA, Budodo R, Bakari C, Francis F, et al. Prevalence of non-
602 falciparum malaria infections among asymptomatic individuals in four regions of Mainland
603 Tanzania. Parasit Vectors. 2024;17:153.
604 5. Hofer LM, Kweyamba PA, Sayi RM, Chabo MS, Maitra SL, Moore SJ, et al. Malaria rapid

- 605 diagnostic tests reliably detect asymptomatic Plasmodium falciparum infections in school-aged
606 children that are infectious to mosquitoes. *Parasit Vectors*. 2023;16:217.
- 607 6. Onken A, Haanshuus CG, Miraji MK, Marijani M, Kibwana KO, Abeid KA, et al. Malaria prevalence
608 and performance of diagnostic tests among patients hospitalized with acute undifferentiated fever
609 in Zanzibar. *Malar J*. 2022;21:54.
- 610 7. Oboh MA, Singh US, Ndiaye D, Badiane AS, Ali NA, Bharti PK, et al. Presence of additional
611 Plasmodium vivax malaria in Duffy negative individuals from Southwestern Nigeria. *Malar J*.
612 2020;19:229.
- 613 8. Tungu P, Kabula B, Nkya T, Machafuko P, Sambu E, Batengana B, et al. Trends of insecticide
614 resistance monitoring in mainland Tanzania, 2004-2020. *Malar J*. 2023;22:100.
- 615 9. Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, et al. Evidence of
616 artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of
617 resistance. *Lancet Infect Dis* 2024. [https://doi.org/10.1016/S1473-3099\(24\)00362-1](https://doi.org/10.1016/S1473-3099(24)00362-1)
- 618 10. Rogier E, Battle N, Bakari C, Seth MD, Nace D, Herman C, et al. Plasmodium falciparum pfhrrp2
619 and pfhrrp3 gene deletions among patients enrolled at 100 health facilities throughout Tanzania:
620 February to July 2021. *Sci Rep*. 2024;14:8158.
- 621 11. Mnzava A, Monroe AC, Okumu F. Anopheles stephensi in Africa requires a more integrated
622 response. *Malar J*. 2022;21:156.
- 623 12. WHO guidelines for malaria, Geneva, Switzerland; 2023. World Health Organization, 2023.
- 624 13. Bohle LF, Abdallah A-K, Galli F, Canavan R, Molesworth K. Knowledge, attitudes and practices
625 towards malaria diagnostics among healthcare providers and healthcare-seekers in Kondoa district,
626 Tanzania: a multi-methodological situation analysis. *Malar J*. 2022;21:224.
- 627 14. Oyegoke OO, Maharaj L, Akoniyon OP, Kwoji I, Roux AT, Adewumi TS, et al. Malaria diagnostic
628 methods with the elimination goal in view. *Parasitol Res*. 2022;121:1867–85.
- 629 15. Agaba BB, Rugera SP, Mpirirwe R, Atekat M, Okubal S, Masereka K, et al. Asymptomatic malaria
630 infection, associated factors and accuracy of diagnostic tests in a historically high transmission
631 setting in Northern Uganda. *Malar J*. 2022;21:392.
- 632 16. Opoku Afriyie S, Addison TK, Gebre Y, Mutala A-H, Antwi KB, Abbas DA, et al. Accuracy of
633 diagnosis among clinical malaria patients: comparing microscopy, RDT and a highly sensitive
634 quantitative PCR looking at the implications for submicroscopic infections. *Malar J*. 2023;22:76.

- 635 17. Mpina M, Stabler TC, Schindler T, Raso J, Deal A, Acuche Pupu L, et al. Diagnostic performance
636 and comparison of ultrasensitive and conventional rapid diagnostic test, thick blood smear and
637 quantitative PCR for detection of low-density Plasmodium falciparum infections during a controlled
638 human malaria infection study in Equatorial Guinea. *Malar J.* 2022;21:99.
- 639 18. Rogier E, Bakari C, Mandara CI, Chiduo MG, Plucinski M, Nace D, et al. Performance of antigen
640 detection for HRP2-based malaria rapid diagnostic tests in community surveys: Tanzania, July-
641 November 2017. *Malar J.* 2022;21:361.
- 642 19. Gillet P, Mori M, Van Esbroeck M, Van den Ende J, Jacobs J. Assessment of the prozone effect in
643 malaria rapid diagnostic tests. *Malar J.* 2009;8:1–7.
- 644 20. Luchavez J, Baker J, Alcantara S, Belizario V, Cheng Q, McCarthy JS, et al. Laboratory
645 demonstration of a prozone-like effect in HRP2-detecting malaria rapid diagnostic tests:
646 implications for clinical management. *Malar J.* 2011;10:1–7.
- 647 21. Agaba BB, Rugera SP, Mpirirwe R, Atekat M, Okubal S, Masereka K, et al. Asymptomatic malaria
648 infection, associated factors and accuracy of diagnostic tests in a historically high transmission
649 setting in Northern Uganda. *Malar J.* 2022;21:392.
- 650 22. Calderaro A, Piccolo G, Chezzi C. The Laboratory Diagnosis of Malaria: A Focus on the Diagnostic
651 Assays in Non-Endemic Areas. *Int J Mol Sci* 2024;25. <http://dx.doi.org/10.3390/ijms25020695>
- 652 23. Ishengoma DS, Francis F, Mmbando BP, Lusingu JPA, Magistrado P, Alifrangis M, et al. Accuracy
653 of malaria rapid diagnostic tests in community studies and their impact on treatment of malaria in
654 an area with declining malaria burden in north-eastern Tanzania. *Malar J.* 2011;10:176.
- 655 24. Yoon J, Jang WS, Nam J, Mihn D-C, Lim CS. An Automated Microscopic Malaria Parasite
656 Detection System Using Digital Image Analysis. *Diagnostics (Basel)* 2021;11.
657 <http://dx.doi.org/10.3390/diagnostics11030527>
- 658 25. Boyce MR, O’Meara WP. Use of malaria RDTs in various health contexts across sub-Saharan
659 Africa: a systematic review. *BMC Public Health.* 2017;17:470.
- 660 26. Johnston SP, Pieniazek NJ, Xayavong MV, Slemenda SB, Wilkins PP, da Silva AJ. PCR as a
661 Confirmatory Technique for Laboratory Diagnosis of Malaria. *J Clin Microbiol.* 2006;44:1087.
- 662 27. Sazed SA, Kibria MG, Alam MS. An Optimized Real-Time qPCR Method for the Effective
663 Detection of Human Malaria Infections. *Diagnostics* 2021 [cited 2024 Aug 11];11.
664 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142979/>

- 665 28. Kamau E, Alemayehu S, Feghali KC, Saunders D, Ockenhouse CF. Multiplex qPCR for Detection
666 and Absolute Quantification of Malaria. *PLoS One*. 2013;8:e71539.
- 667 29. Lazrek Y, Florimond C, Volney B, Discours M, Mosnier E, Houzé S, et al. Molecular detection of
668 human Plasmodium species using a multiplex real time PCR. *Sci Rep*. 2023;13:11388.
- 669 30. Nsanzabana C, Arieu F, Beck H-P, Ding XC, Kamau E, Krishna S, et al. Molecular assays for
670 antimalarial drug resistance surveillance: A target product profile. *PLoS One*. 2018;13:e0204347.
- 671 31. Mahende C, Ngasala B, Lusingu J, Yong T-S, Lushino P, Lemnge M, et al. Performance of rapid
672 diagnostic test, blood-film microscopy and PCR for the diagnosis of malaria infection among febrile
673 children from Korogwe District, Tanzania. *Malar J*. 2016;15:391.
- 674 32. Zoghi S, Mehrizi AA, Raeisi A, Haghdooost AA, Turki H, Safari R, et al. Survey for asymptomatic
675 malaria cases in low transmission settings of Iran under elimination programme. *Malar J*.
676 2012;11:126.
- 677 33. Hayuma PM, Wang CW, Liheluka E, Baraka V, Madebe RA, Minja DTR, et al. Prevalence of
678 asymptomatic malaria, submicroscopic parasitaemia and anaemia in Korogwe District, north-
679 eastern Tanzania. *Malar J*. 2021;20:424.
- 680 34. Mandai SS, Francis F, Challe DP, Seth MD, Madebe RA, Petro DA, et al. High prevalence and risk
681 of malaria among asymptomatic individuals from villages with high prevalence of artemisinin
682 partial resistance in Kyerwa district of Kagera region, north-western Tanzania. *Malar J*.
683 2024;23:197.
- 684 35. Health Organization W. Methods for surveillance of antimalarial drug efficacy methods for
685 surveillance of antimalarial drug efficacy. [apps.who.int](https://apps.who.int/iris/bitstream/handle/10665/44048/9789241597531_eng.pdf); 2009 [cited 2023 Nov 6].
686 https://apps.who.int/iris/bitstream/handle/10665/44048/9789241597531_eng.pdf
- 687 36. Ngasala B, Mutemi DD, Mwaiswelo RO. Diagnostic Performance of Malaria Rapid Diagnostic
688 Test and Microscopy Compared with PCR for Detection of Plasmodium falciparum Infections
689 among Primary Schoolchildren in Kibiti District, Eastern Tanzania: An Area with Moderate Malaria
690 Transmission. *Am J Trop Med Hyg*. 2019;101:809–11.
- 691 37. Tanzania N. National guidelines for malaria diagnosis and treatment. *Dar Salaam Med Stud J*.
692 2006;
- 693 38. Standard Treatment Guideline and National Essential Medicines lists for Tanzania Mainland;
694 2021.

- 695 39. WHO. Basic Malaria Microscopy 2010, Geneva: World Health Organization; 2010.
- 696 40. Manjurano A, Omolo JJ, Lyimo E, Miyaye D, Kishamawe C, Matemba LE, et al. Performance
697 evaluation of the highly sensitive histidine-rich protein 2 rapid test for plasmodium falciparum
698 malaria in North-West Tanzania. *Malar J.* 2021;20:58.
- 699 41. Moyeh MN, Ali IM, Njimoh DL, Nji AM, Netongo PM, Evehe MS, et al. Comparison of the
700 accuracy of four malaria diagnostic methods in a high transmission setting in coastal Cameroon. *J*
701 *Parasitol Res.* 2019;2019:1417967.
- 702 42. Juliano JJ, Giesbrecht DJ, Simkin A, Fola AA, Lyimo BM, Pereus D, et al. Prevalence of mutations
703 associated with artemisinin partial resistance and sulfadoxine–pyrimethamine resistance in 13
704 regions in Tanzania in 2021: a cross-sectional survey. *The Lancet Microbe* 2024 [cited 2024 Aug
705 19];0. <http://www.thelancet.com/article/S2666524724001605/abstract>
- 706 43. Chacha GA, Francis F, Mandai SS, Seth MD, Madebe RA, Challe DP, et al. Prevalence and drivers
707 of malaria infections among asymptomatic individuals from selected communities in five regions of
708 Mainland Tanzania with varying transmission intensities . *bioRxiv.* 2024. p.
709 2024.06.05.24308481. <https://www.medrxiv.org/content/10.1101/2024.06.05.24308481v1>
- 710 44. Kalinga AK, Ishengoma DS, Kavishe R, Temu L, Mswanya C, Mwanziva C, et al. The use of Fionet
711 technology for external quality control of malaria rapid diagnostic tests and monitoring health
712 workers' performance in rural military health facilities in Tanzania. *PLoS One.* 2018;13:e0208583.
- 713 45. Amadi E, Ebenezer A, Daworiye P. Comparison of Rapid Malaria Test and Laboratory
714 Microscopy Investigation for Community-Based Active Surveillance of Asymptomatic Falciparum
715 Malaria in Yenagoa, Niger Delta, Nigeria. *jasem* 2010 [cited 2024 Aug 18];14.
716 <https://www.ajol.info/index.php/jasem/article/view/57851>
- 717 46. Ogunfowokan O, Ogunfowokan BA, Nwajei AI. Sensitivity and specificity of malaria rapid
718 diagnostic test (mRDT CareStat™) compared with microscopy amongst under five children
719 attending a primary care clinic in southern Nigeria. *Afr J Prim Health Care Fam Med.* 2020;12:e1–8.
- 720 47. Odhiambo F, Buff AM, Moranga C, Moseti CM, Wesongah JO, Lowther SA, et al. Factors
721 associated with malaria microscopy diagnostic performance following a pilot quality-assurance
722 programme in health facilities in malaria low-transmission areas of Kenya, 2014. *Malar J.*
723 2017;16:371.
- 724 48. Jemere KA, Melaku MY, Jemeber TH, Abate MA. Performance evaluation of laboratory

- 725 professionals on malaria microscopy at health facilities in Bahir Dar city administration, Northwest
726 Ethiopia. PLoS One. 2018;13:e0203420.
- 727 49. Sori G, Zewdie O, Tadele G, Samuel A. External quality assessment of malaria microscopy
728 diagnosis in selected health facilities in Western Oromia, Ethiopia. Malar J. 2018;17:233.
- 729 50. Lapierre J, Holler C. Malaria. *Nouv Presse Med*. 1974;3:1669–70.
- 730 51. Awosolu OB, Yahaya ZS, Farah Haziqah MT. Prevalence, parasite density and determinants of
731 falciparum malaria among febrile children in some Peri-urban communities in southwestern
732 Nigeria: A cross-sectional study. *Infect Drug Resist*. 2021;14:3219–32.
- 733 52. White M, Watson J. Age, exposure and immunity. *Elife*
734 2018;7.<http://dx.doi.org/10.7554/eLife.40150>
- 735 53. Mfuh KO, Achonduh-Atijegbe OA, Bekindaka ON, Esemu LF, Mbakop CD, Gandhi K, et al. A
736 comparison of thick-film microscopy, rapid diagnostic test, and polymerase chain reaction for
737 accurate diagnosis of Plasmodium falciparum malaria. *Malar J*. 2019;18:73.
- 738 54. Mouatcho JC, Goldring JPD. Malaria rapid diagnostic tests: challenges and prospects. *J Med*
739 *Microbiol*. 2013;62:1491–505.
- 740 55. Madkhali AM, Ghzwani AH, Al-Mekhlafi HM. Comparison of rapid diagnostic test, microscopy,
741 and polymerase chain reaction for the detection of Plasmodium falciparum malaria in a low-
742 transmission area, Jazan region, southwestern Saudi Arabia. *Diagnostics (Basel)*. 2022;12:1485.
- 743 56. Berzosa P, de Lucio A, Romay-Barja M, Herrador Z, González V, García L, et al. Comparison of
744 three diagnostic methods (microscopy, RDT, and PCR) for the detection of malaria parasites in
745 representative samples from Equatorial Guinea. *Malar J*. 2018;17:333.
- 746 57. Alareqi LMQ, Mahdy MAK, Lau Y-L, Fong M-Y, Abdul-Ghani R, Ali AA, et al. Field evaluation of a
747 PfHRP-2/pLDH rapid diagnostic test and light microscopy for diagnosis and screening of falciparum
748 malaria during the peak seasonal transmission in an endemic area in Yemen. *Malar J*. 2016;15:49.
- 749 58. Laurent A, Schellenberg J, Shirima K, Ketende SC, Alonso PL, Mshinda H, et al. Performance of
750 HRP-2 based rapid diagnostic test for malaria and its variation with age in an area of intense
751 malaria transmission in southern Tanzania. *Malar J*. 2010;9:294.
- 752 59. Siahaan L, Panggabean M, Panggabean YC. RDT accuracy based on age group in hypoendemic
753 malaria. *IOP Conf Ser Earth Environ Sci*. 2018;125:012018.
- 754 60. Abeku TA, Kristan M, Jones C, Beard J, Mueller DH, Okia M, et al. Determinants of the accuracy

755 of rapid diagnostic tests in malaria case management: evidence from low and moderate
756 transmission settings in the East African highlands. *Malar J.* 2008;7:202.

757 61. Swarthout TD, Counihan H, Senga RKK, van den Broek I. Paracheck-Pf accuracy and recently
758 treated *Plasmodium falciparum* infections: is there a risk of over-diagnosis? *Malar J.* 2007;6:58.

759 62. Murungi M, Fulton T, Reyes R, Matte M, Ntaro M, Mulogo E, et al. Improving the specificity of
760 *Plasmodium falciparum* malaria diagnosis in high-transmission settings with a two-step rapid
761 diagnostic test and microscopy algorithm. *J Clin Microbiol.* 2017;55:1540–9.

762

Table 1. Baseline characteristics of study participants

Characteristics	Kitoma	Kitwechenkura	Nyakabwera	Rubuga	Ruko	Total
Examined, n (%)	709 (15.9)	769 (17.3)	1243 (27.9)	974 (21.9)	759 (17.0)	4454
Sex, n (%)						
Female	393 (55.4)	459 (59.7)	749 (60.3)	584 (60.0)	458 (60.3)	2643 (59.3)
Male	316 (44.6)	310 (40.3)	494 (39.7)	390 (40.0)	301 (39.7)	1811 (40.7)
Age in years, median (IQR)	16 (8-38)	15 (5-37)	14 (6-35)	12 (5-33)	14(7-36)	14.1 (6.7-36.0)
Age group (years), n (%)						
<5	154 (21.7)	131 (17.0)	205 (16.5)	180 (18.5)	165 (21.7)	835 (18.8)
5 - <15	205 (28.9)	230 (29.9)	413 (33.2)	351 (36.0)	274 (36.1)	1473 (33.1)
15+	350 (49.4)	408 (53.1)	625 (50.3)	443 (45.5)	320 (42.2)	2146 (48.2)
History of fever in the past 48 hours, n (%)						
Yes	296 (41.8)	163 (21.2)	130 (10.5)	436 (44.8)	316 (41.6)	1341 (30.1)
No	413 (58.3)	606 (78.8)	1113 (89.5)	538 (55.2)	443 (58.4)	3113 (69.9)
Fever at presentation (temp \geq 37.5°C)	32 (4.5)	21 (2.7)	23 (1.9)	41 (4.2)	21 (2.8)	138 (3.1)
History of use of any medication in the past seven days						
Yes	60 (8.5)	54 (7.0)	34 (2.7)	64 (6.6)	77 (10.1)	289 (6.5)
No	6549 (91.5)	715 (93.0)	1209 (97.3)	910 (93.4)	682 (89.9)	4195 (94.5)
History of AL use in the past seven days						
Yes	55 (91.7)	46 (85.2)	29 (85.3)	62 (96.9)	66 (85.7)	258 (89.3)
No	5 (8.3)	8 (14.8)	5 (14.7)	2 (3.1)	11 (14.3)	31 (10.7)

763

n: Number of observations; temp: Axillary temperature (\geq 37.5°C); IQR: Inter-quartile range; AL: Artemether-Lumefantrine

764 **Table 2. Prevalence of malaria parasites by RDT, microscopy and qPCR**
765

Variable	# Positive by RDT, n (%)	# Positive by microscopy, n (%)	# Positive by qPCR, n (%)
Overall (n=4454)	1979 (44.4)	1431(32.1)	1771(39.8)
Sex			
Female	1089 (41.2)	808 (30.6)	992 (37.5)
Male	890 (49.1)	623 (34.4)	779 (43.0)
p-value	<0.001	0.007	<0.001
Age group (years)			
<5	452 (54.1)	259 (31.0)	335 (40.1)
5 - <15	874 (59.3)	681 (46.2)	794 (53.9)
≥15	653 (30.4)	491 (22.9)	642 (29.9)
p-value	<0.001	<0.001	<0.001
Village			
Kitoma	440 (62.1)	345 (48.7)	395 (55.7)
Kitwechenkura	241 (31.3)	176 (22.9)	259 (33.7)
Nyakabwera	180 (14.5)	116 (9.3)	173 (13.9)
Rubuga	598 (61.4)	401 (41.2)	544 (55.9)
Ruko	520 (68.5)	392 (51.7)	400 (52.7)
p-value	<0.001	<0.001	<0.001
History of fever past 48 hours			
Yes	1186 (88.4)	846 (63.1)	1021 (76.1)
No	793 (25.5)	584 (18.8)	750 (24.1)
p-value	<0.001	<0.001	<0.001
Fever at presentation (axillary temp ≥ 37.5°C)			
Yes	108 (79.4)	93 (68.4)	101 (74.3)
No	1871 (43.3)	1338 (31.0)	1670 (38.7)

p-value	<0.001	<0.001	<0.001
History of using AL in the past seven days			
Yes	249 (96.5)	97 (37.6)	165 (64.0)
No	1730 (41.2)	1333 (31.8)	1606 (38.3)
p-value	<0.001	0.053	<0.001

766 **n: Number of observations; RDTs: Rapid diagnostic tests; qPCR: Quantitative Polymerase Chain Reaction; AL: Artemether-**
 767 **Lumefantrine; temp: Axillary temperature; #: number of individuals with positive results**

768
769
770

Table 3. Prevalence of Plasmodium species by microscopy and qPCR

Plasmodium species	microscopy, n (%)	qPCR, n (%)
All species (n=4454)	1431(32.1%)	1771(39.8%)
<i>P. falciparum</i>	1279 (28.7)	1572 (35.3)
<i>P. ovale</i>	12 (0.3)	24 (0.5)
<i>P. malariae</i>	7 (0.2)	16 (0.4)
<i>P. falciparum/P. malariae</i>	93 (2.1)	40 (0.9)
<i>P. falciparum/P. ovale</i>	39 (0.9)	114 (2.6)
<i>P. ovale/P. malariae</i>	0 (0)	2 (0.04)
<i>P. falciparum/P. malariae/P. ovale</i>	1 (0.02)	3 (0.07)

771 **n: Number of observations; qPCR: Quantitative Polymerase Chain Reaction**

772

773 **Table 4. Geometric mean parasite density (GMPD) by microscopy and qPCR**

Variable	Plasmodium species GMPD (95% CI) by microscopy			Plasmodium species GMPD (95% CI) by qPCR		
	<i>P. falciparum</i>	<i>P. ovale</i>	<i>P. malariae</i>	<i>P. falciparum</i>	<i>P. ovale</i>	<i>P. malariae</i>
Sex						
Male	759 (635-908)	118 (67-209)	114 (79-163)	1401 (1143-1717)	37 (24-57)	44 (17-116)
Female	563 (481-660)	136 (67-276)	136 (95-195)	1017 (849-1219)	50 (30-85)	37 (16-85)
p-value	0.014	0.747	0.477	0.015	0.225	0.528
Age group						
<5 years	1915 (1398-2623)	209 (70-629)	288 (165-504)	2076 (1462-2948)	118 (59-236))	67 (15-300)
5 - <15 years	850 (724-998)	94 (54-164)	105 (80-137)	1679 (1386-2034)	36 (23-56)	46 (23-91)
≥15 years	246 (206-293)	166 (57-481)	63 (28-142)	566 (460-697)	21 (10-42)	25 (7-91)
p-value	<0.001	0.458	<0.001	<0.001	0.002	0.272
Village						
Kitoma	633 (499-804)	50 (35-72)	121 (70-211)	1002 (769-1305)	41 (22-78)	52 (3-1065)
Kitwechenkura	581 (411-821)	116 (21-642)	166 (65-423)	262 (151-457)	34 (12-92)	47 (9-232)
Nyakabwera	428 (279-657)	229 (24-2150)	281 (47-1684)	98 (81-124)	53 (10-272)	29 (3-323)
Rubuga	579 (460-728)	307 (93-1012)	115 (58-227)	1625 (1268-2084)	37 (20-67)	55 (6-167)
Ruko	847 (679-1057)	106 (55-205)	112 (78-161)	3353 (2407-4670)	68(38-121)	8 (5-22)
p-value	0.034	0.100	0.640	<0.001	0.795	0.626

774 **GMPD: Geometric Mean Parasite Density**

775

776 **Table 5. Performance of RDT and microscopy with qPCR as a reference method**

		qPCR			Value (95% Confidence interval)					
		Pos	Neg	Total	Sensitivity	Specificity	PPV	NPV	Accuracy	K-value
RDT	Pos	1651	328	1979	93.2% (92.0-94.4)	87.8% (86.5-89.0)	83.4% (82.0-84.8)	95.2% (94.3-95.9)	89.9% (89.0-90.8)	0.79 (0.78-0.81)
	Neg	120	2355	2475						
microscopy	Pos	1328	103	1,431	75.0% (72.9-77.0)	96.2% (95.4-96.9)	92.8% (91.4-94.0)	85.3% (84.3-86.3)	87.7% (86.7-88.7)	0.74 (0.71-0.76)
	Neg	443	2579	3023						

777
778
779

780 Table 6A. Predictors of a risk sensitivity of RDT and microscopy results among individuals with positive results by qPCR
781

Variable/covariate	RDTs			Microscopy		
	Sensitivity (%; 95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Sensitivity (%; 95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Sex						
Male	745/779 (95.6, 94.0-96.9)	Ref	Ref	588/779 (75.5, 72.3-78.4)	Ref	Ref
Female	906/992 (91.3, 89.4-92.9)	0.48 (0.32-0.72) ***	0.52 (0.31-0.86) *	740/992 (74.6, 71.8-77.2)	0.95 (0.77-1.18)	1.14(0.86-1.51)
Age group						
<5 years	329/335(98.2, 96.1-99.2)	Ref	Ref	245/335(73.1, 68.1-77.6)	Ref	Ref
5 - <15 years	768/794(96.7, 95.2-97.8)	0.54 (0.20-1.24)	0.53 (0.18-1.34)	651/794 (82.0, 79.2-84.5)	1.67(1.23-2.26) ***	2.37 (1.58-3.55) ***
≥15 years	554/642 (86.3, 83.4-88.7)	0.11 (0.04-0.24) ***	0.18 (0.1-0.42) ***	432/642 (67.3, 63.6-70.8)	0.76 (0.56-1.01)	1.45 (0.98-2.15)
History of fever						
No	642/750 (85.6, 82.9-87.9)	Ref	Ref	507/750 (67.6, 64.2-70.9)	Ref	Ref
Yes	1009/1021 (98.8, 98.0-99.3)	14.14 (8.05-27.27) ***	8.78 (4.73-17.69) ***	821/1021 (80.4, 77.9-82.7)	1.97 (1.58-2.45) ***	1.35 (1.02-1.79)
Fever at presentation						
No	1550/1670(92.8, 91.5-94.0)	Ref	Ref	1236/1670 (74.0, 71.976.1)	Ref	Ref
Yes	101/101 (100, 96.3-100)	1.29 (1.03-1.62) *	1.03 (0.76-1.39)	92/101 (91.1, 83.9-95.2)	1.24 (1.09-1.42) **	1.05 (0.88-1.26)
Parasite density						
<100	302/391 (77.2, 72.8-81.1)	Ref	Ref	158/391 (40.4, 35.7-45.3)	Ref	Ref
100-1000	426/454 (93.8, 91.2-95.7)	1.39 (0.85-2.24)	1.75 (0.98-3.14)	321/454 (70.7, 66.4-74.7)	2.45(1.60-3.79) ***	2.81 (1.74-4.58) ***
1001-5000	338/339 (99.7, 98.3-99.9)	4.00 (2.34-6.99) ***	5.36 (2.82-10.48) ***	287/339 (84.7, 80.4-88.1)	5.11(3.37-7.85) ***	5.86 (3.66-9.52) ***
5001-10000	129/129 (100, 97.1-100)	44.21 (18.76-129.96) ***	56.76 (21.76-180.9) ***	119/129 (92.2, 86.3-95.7)	14.11 (9.45-21.38) ***	20.68 (13.0-33.61) ***
>10000	456/458 (99.6, 98.4-99.9)	81.51 (24.63-504.50) ***	104.67 (27.83-6927) ***	443/458 (96.7, 94.7-98.0)	70.92 (39.71-134.23) ***	146.1 (76.5-294.4) ***
Village of residence						
Kitwechenkura	220/259(84.9, 80.1-88.8)	Ref	Ref	167/259 (64.5, 58.5-70.1)	Ref	Ref

Nyakabwera	154/173(89.0, 83.5-92.9)	1.44 (0.81-2.63)	6.30 (2.90-14.2) ***	92/173 (53.2, 45.8-60.5)	0.63 (0.42-0.93) *	1.95 (1.16-3.28) *
Rubuga	361/395(91.4, 88.2-93.7)	1.88 (1.15-3.08) *	4.17 (2.12-8.41) ***	336/395 (85.1, 81.2-88.2)	3.14 (2.16-4.59) ***	9.27 (5.77-15.08) ***
Kitoma	529/544(97.2, 95.5-98.3)	6.25 (3.45-11.92) ***	9.49 (4.47-21.2) ***	374/544 (68.8, 64.7-72.5)	1.21 (0.89-1.65)	1.65 (1.11-2.46) *
Ruko	387/400(96.8, 94.5-98.1)	5.28 (2.83-10.47) ***	14.6 (6.55-34.6) ***	359/400 (89.8, 86.4-92.4)	4.82 (3.22-7.34) ***	14.8 (8.98-24.92) ***

OR: Odds ratio, CI: Confidence interval, ***p<0.001, **p<0.01, *p<0.05

782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808

809
810

Table 6B. Predictors of specificity of RDT and microscopy results among individuals with negative results by qPCR

Variable/covariate	RDTs			Microscopy		
	Specificity (% 95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Specificity (% 95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Sex						
Male	887/1032 (85.9, 83.7-87.9)	Ref	Ref	997/1032 (96.6, 95.3-97.6)	Ref	Ref
Female	1468/1651 (88.9, 87.3-90.3)	1.31 (1.04-1.65) *	1.01 (0.74-1.36)	1583/1651 (95.9, 94.8-96.7)	0.82 (0.53-1.23)	0.84 (0.54-1.28)
Age group						
<5 years	377/500 (75.4, 71.4-79.0)	Ref	Ref	486/500 (97.2, 95.4-98.3)	Ref	Ref
5 - <15 years	573/679 (84.4, 81.5-86.9)	1.76 (1.32-2.36) ***	0.87 (0.59-1.28)	649/679 (95.6, 93.8-96.9)	0.62 (0.32-1.17)	0.47 (0.23-0.89)
≥15 years	1405/1504 (93.4, 92.1-94.6)	4.63 (3.47-6.19) ***	4.69 (3.24-6.81) ***	1445/1504 (96.1, 95.0-96.9)	0.71(0.38-1.24)	0.62 (0.32-1.11)
History of fever						
No	2212/2363 (93.6, 92.6-94.5)	Ref	Ref	2286/2363 (96.7, 95.9-97.4)	Ref	Ref
Yes	143/320 (44.7, 39.3-50.2)	0.05 (0.04-0.07) ***	0.08 (0.06-0.12) ***	294/320(91.9, 88.4-94.4)	0.38 (0.24-0.61) ***	0.52 (0.32-0.87) *
Fever at presentation						
No	2327/2648 (87.9, 86.6-89.1)	Ref	Ref	2546/2648 (96.1, 95.3-96.8)	Ref	Ref
Yes	28/35 (80.0, 64.1-90.0)	0.55 (0.25-1.38)	0.59 (0.22-1.82)	34/35 (97.1, 85.5-99.5)	0.97 (0.74-1.26)	0.94 (0.72-1.23)
Village of residence						
Kitwechenkura	489/510 (95.9, 93.8-97.3)	Ref	Ref	501/510 (98.2, 96.7-99.1)	Ref	Ref
Nyakabwera	1044/1070 (97.6, 96.5-98.3)	1.72 (0.95-3.09)	1.96 (1.05-3.60) *	1046/1070 (97.8, 96.7-98.5)	0.78 (0.34-1.64)	0.80 (0.35-1.68)
Rubuga	235/314 (74.8, 69.8-79.3)	0.13 (0.08-0.21) ***	0.13(0.07-0.23) ***	304/314 (96.8, 94.2-98.3)	0.55 (0.21-1.37)	0.59 (0.23-1.49)
Kitoma	361/430 (84.0, 80.2-87.1)	0.22 (0.13-0.37) ***	0.32(0.18-0.55) ***	403/430 (93.7, 91.0-95.6)	0.27 (0.12-0.56) ***	0.29 (0.13-0.61) **
Ruko	226/359 (63.0, 57.8-67.8)	0.07 (0.04-0.12) ***	0.08 (0.05-0.14) ***	326/359 (90.8, 87.4-93.4)	0.18 (0.08-0.36) ***	0.20 (0.09-0.41) ***

OR: Odds ratio, CI: Confidence interval, ***p<0.001, **p<0.01, *p<0.05

811
812